Abstract
The development of peptide receptor scintigraphy in combination with radioiodinated somatostatin analogues allowed the in vivo demonstration of somatostatin-receptorpositive tumors in patients [1]. Later, other radiolabeled somatostatin analogues were developed, two of which subsequently became commercially available. With the advent, over the past decade, of positron emission tomography (PET) tracers for somatostatin receptor imaging, superior image quality and increased sensitivity in tumor site detection have become possible, as confirmed by several research groups. In the 1990’s, attempts at treatment with radiolabeled somatostatin analogues were undertaken in patients with inoperable and/or metastasized neuroendocrine tumors. Improvements in the peptides (higher receptor affinity) and the available radionuclides (β instead of γ emission), together with precautions to limit the radiation dose to the kidneys and bone marrow, led to better results and a virtually negligible percentage of serious adverse events.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Krenning EP, Bakker WH, Breeman WA et al (1989) Localization of endocrine related tumors with radioiodinated analogue of somatostatin. Lancet 1:242–245
Balon HR, Goldsmith SJ, Siegel BA et al (2001) Procedure guideline for somatostatin receptor scintigraphy with 111Inpentetreotide. J Nucl Med 42:1134–1138
Gibril F, Reynolds JC, Chen CC et al (1999) Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 40:539–553
Reubi JC (1997) Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 41:63–70
Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtypeselective ligands. Eur J Nucl Med 28:836–846
Reubi JC, Waser B, Krenning EP et al (1994) Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol 271:371–378
Krenning EP, Kwekkeboom DJ, Bakker WH et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731
Kwekkeboom DJ, Krenning EP, Bakker WH et al (1993) Somatostatin analogue scintigraphy in carcinoid tumors. Eur J Nucl Med 20:283–292
Westlin JE, Janson ET, Arnberg H et al (1993) Somatostatin receptor scintigraphy of carcinoid tumours using the [111In DTPA D Phe1] octreotide. Acta Oncol 32:783–786
De Kerviler E, Cadiot G, Lebtahi R et al (1994) Somatostatin receptor scintigraphy in forty eight patients with the Zollinger Ellison syndrome. Eur J Nucl Med 21:1191–1197
Gibril F, Reynolds JC, Doppman JL et al (1996) Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125:26–34
Lebtahi R, Cadiot G, Sarda L et al (1997) Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 38:853–858
Menda Y, Kahn D (2002) Somatostatin receptor imaging of nonsmall lung cancer with 99mTc depreotide. Semin Nucl Med 32:92–96
Lebtahi R, Le Cloirec J, Houzard C et al (2002) Detection of Neuroendocrine Tumors: (99m)Tc-P829 Scintigraphy Compared with (111)In-Pentetreotide Scintigraphy. J Nucl Med 43:889–895
Hofmann M, Maecke H, Börner R et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751–1757
Quigley AM, Buscombe JR, Shah T et al (2005) Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours. An observational, cross-sectional study. Neuroendocrinology 82:215–220
Belhocine T, Foidart J, Rigo P et al (2002) Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun 23:727–734
Koopmans KP, de Vries EG, Kema IP et al (2006) Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 7:728–734
Arnold R, Benning R, Neuhaus C et al (1993) Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 54(Suppl 1):72–75
Valkema R, de Jong M, Bakker WH et al (2002) Phase I study of peptide receptor radionuclide theraply with [111In-DTPA0] Octreotide: the Rotterdam experience. Semin Nucl Med 32:110–122
Anthony LB, Woltering EA, Espanan GD et al (2002) Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32:123–132
Bodei L, Cremonesi M, Zoboli S et al (2003) Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imag 30:207–216
Waldherr C, Pless M, Maecke HR et al (2001) The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12:941–945
Waldherr C, Pless M, Maecke HR et al (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:610–616
Valkema R, Pauwels S, Kvols LK et al (2006) Survival and response after peptide receptor radionuclide therapy with [90YDOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36:147–156
Valkema R, Pauwels SA, Kvols LK et al (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med 46(Suppl 1):83S–91S
Reubi JC, Schaer JC, Waser B et al (2000) Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273–282
Kwekkeboom DJ, Bakker WH, Kooij PP et al (2001) [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 28:1319–1325
Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130
De Keizer B, van Aken MO, Feelders RA et al (2008) Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3] octreotate. Eur J Nucl Med Mol Imag 35:749–755
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Verlag Italia
About this chapter
Cite this chapter
Kwekkeboom, D.J. (2010). Neuroendocrine Tumors of the Abdomen: Imaging and Therapy. In: Hodler, J., Zollikofer, C.L., Von Schulthess, G.K. (eds) Diseases of the Abdomen and Pelvis 2010–2013. Springer, Milano. https://doi.org/10.1007/978-88-470-1637-8_32
Download citation
DOI: https://doi.org/10.1007/978-88-470-1637-8_32
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1636-1
Online ISBN: 978-88-470-1637-8
eBook Packages: MedicineMedicine (R0)